{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:53:43Z","timestamp":1773053623766,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T00:00:00Z","timestamp":1478476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T00:00:00Z","timestamp":1478476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1038\/bmt.2016.269","type":"journal-article","created":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T14:42:21Z","timestamp":1478529741000},"page":"438-444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation"],"prefix":"10.1038","volume":"52","author":[{"given":"M A","family":"Kharfan-Dabaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0375-7570","authenticated-orcid":false,"given":"R","family":"Parody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Lopez-Godino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Lopez-Corral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Falantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Ort\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Barba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Valc\u00e1rcel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Esquirol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J L","family":"Pi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Solano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Tsalatsanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Pidala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Anasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"Perez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,7]]},"reference":[{"key":"BFbmt2016269_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/asheducation-2014.1.21","volume":"2014","author":"ML Sorror","year":"2014","unstructured":"Sorror ML, Estey E . Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. Hematology Am Soc Hematol Educ Program 2014; 2014: 21\u201333.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFbmt2016269_CR2","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.bbmt.2013.01.027","volume":"19","author":"MA Kharfan-Dabaja","year":"2013","unstructured":"Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M . Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013; 19: 1006\u20131012.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016269_CR3","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","volume":"361","author":"MM Hsieh","year":"2009","unstructured":"Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009; 361: 2309\u20132317.","journal-title":"N Engl J Med"},{"key":"BFbmt2016269_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/bmt.2015.293","volume":"51","author":"D Baronciani","year":"2016","unstructured":"Baronciani D, Angelucci E, Potschger U, Gaziev J, Yesilipek A, Zecca M et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010. Bone Marrow Transplant 2016; 51: 536\u2013541.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016269_CR5","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/bmt.2013.35","volume":"48","author":"M Ayas","year":"2013","unstructured":"Ayas M, Nassar A, Hamidieh AA, Kharfan-Dabaja M, Othman TB, Elhaddad A et al. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure. Bone Marrow Transplant 2013; 48: 1168\u20131172.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016269_CR6","first-page":"4576","volume":"110","author":"SJ Lee","year":"2007","unstructured":"Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576\u20134583.","journal-title":"Blood"},{"key":"BFbmt2016269_CR7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.bbmt.2010.09.012","volume":"17","author":"A Woolfrey","year":"2011","unstructured":"Woolfrey A, Klein JP, Haagenson M, Spellman S, Petersdorf E, Oudshoorn M et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 885\u2013892.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016269_CR8","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","volume":"117","author":"G Socie","year":"2011","unstructured":"Socie G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR et al. Chronic Graft-Versus-Host Disease: long-term results from a randomized trial on Graft-Versus-Host Disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011; 117: 6375\u20136382.","journal-title":"Blood"},{"key":"BFbmt2016269_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","volume":"127","author":"RA Marsh","year":"2016","unstructured":"Marsh RA, Lane A, Mehta PA, Neumeier L, Jodele S, Davies SM et al. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. Blood 2016; 127: 503\u2013512.","journal-title":"Blood"},{"key":"BFbmt2016269_CR10","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.bbmt.2011.02.002","volume":"17","author":"SM Devine","year":"2011","unstructured":"Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A et al. Low risk of chronic Graft-Versus-Host Disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant 2011; 17: 1343\u20131351.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016269_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard Graft-Versus-Host Disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855\u2013864.","journal-title":"Lancet Oncol"},{"key":"BFbmt2016269_CR12","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.bbmt.2005.12.034","volume":"12","author":"A Bacigalupo","year":"2006","unstructured":"Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic Graft-Versus-Host Disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560\u2013565.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016269_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kr\u00f6ger","year":"2016","unstructured":"Kr\u00f6ger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M et al. Antilymphocyte globulin for prevention of chronic Graft-Versus-Host Disease. N Engl J Med 2016; 374: 43\u201353.","journal-title":"N Engl J Med"},{"key":"BFbmt2016269_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbmt.2003.12.305","volume":"10","author":"C Cutler","year":"2004","unstructured":"Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ et al. Sirolimus and tacrolimus without methotrexate as Graft-Versus-Host Disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 328\u2013336.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016269_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.bbmt.2008.03.007","volume":"14","author":"JA Perez-Simon","year":"2008","unstructured":"Perez-Simon JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Camara R et al. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as Graft-Versus-Host Disease prophylaxis. Biol Blood Marrow Transplant 2008; 14: 664\u2013671.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016269_CR16","first-page":"CD010280","volume":"25","author":"M Kharfan-Dabaja","year":"2014","unstructured":"Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B et al. Mycophenolate mofetil versus methotrexate for prevention of Graft-Versus-Host Disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev 2014; 25: CD010280.","journal-title":"Cochrane Database Syst Rev"},{"key":"BFbmt2016269_CR17","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3324\/haematol.2012.067140","volume":"97","author":"J Pidala","year":"2012","unstructured":"Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012; 97: 1882\u20131889.","journal-title":"Haematologica"},{"key":"BFbmt2016269_CR18","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","volume":"124","author":"C Cutler","year":"2014","unstructured":"Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D et al. Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 2014; 124: 1372\u20131377.","journal-title":"Blood"},{"key":"BFbmt2016269_CR19","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.bbmt.2012.06.004","volume":"18","author":"Z Al-Kadhimi","year":"2012","unstructured":"Al-Kadhimi Z, Gul Z, Rodriguez R, Chen W, Smith D, Mitchell A et al. Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute Graft-Versus-Host Disease prophylaxis for unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1734\u20131744.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016269_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/bmt.2012.175","volume":"48","author":"SK Khaled","year":"2013","unstructured":"Khaled SK, Palmer J, Stiller T, Senitzer D, Maegawa R, Rodriguez R et al. A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant. Bone Marrow Transplant 2013; 48: 278\u2013283.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016269_CR21","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/bmt.2015.192","volume":"50","author":"R Nelson","year":"2015","unstructured":"Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J et al. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. Bone Marrow Transplant 2015; 50: 1487\u20131489.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016269_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/bmt.2014.220","volume":"50","author":"R Parody","year":"2015","unstructured":"Parody R, Lopez-Corral L, Godino OL, Cadenas IG, Martinez AP, Vazquez L et al. GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. Bone Marrow Transplant 2015; 50: 121\u2013126.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016269_CR23","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016269_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic Graft-Versus-Host Disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016269_CR25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","volume":"11","author":"VT Ho","year":"2005","unstructured":"Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571\u2013575.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016269_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255\u2013267.","journal-title":"Ann Intern Med"},{"key":"BFbmt2016269_CR27","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487\u20131496.","journal-title":"N Engl J Med"},{"key":"BFbmt2016269_CR28","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1182\/blood.V98.12.3221","volume":"98","author":"JM Zaucha","year":"2001","unstructured":"Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic Graft-Versus-Host Disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221\u20133227.","journal-title":"Blood"},{"key":"BFbmt2016269_CR29","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","volume":"98","author":"A Bacigalupo","year":"2001","unstructured":"Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P et al. Antithymocyte globulin for Graft-Versus-Host Disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942\u20132947.","journal-title":"Blood"},{"key":"BFbmt2016269_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","volume":"17","author":"I Walker","year":"2016","unstructured":"Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol 2016; 17: 164\u2013173.","journal-title":"Lancet Oncol"},{"key":"BFbmt2016269_CR31","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/01.tp.0000259555.29762.f0","volume":"83","author":"E Uss","year":"2007","unstructured":"Uss E, Yong SL, Hooibrink B, van Lier RA, ten Berge IJ . Rapamycin enhances the number of alloantigen-induced human CD103+CD8+ regulatory T cells in vitro. Transplantation 2007; 83: 1098\u20131106.","journal-title":"Transplantation"},{"key":"BFbmt2016269_CR32","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","volume":"105","author":"M Battaglia","year":"2005","unstructured":"Battaglia M, Stabilini A, Roncarolo MG . Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105: 4743\u20134748.","journal-title":"Blood"},{"key":"BFbmt2016269_CR33","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1182\/blood-2007-01-069294","volume":"110","author":"FM Marty","year":"2007","unstructured":"Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV et al. Sirolimus-based Graft-Versus-Host Disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007; 110: 490\u2013500.","journal-title":"Blood"},{"key":"BFbmt2016269_CR34","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1097\/01.tp.0000260142.38619.9c","volume":"83","author":"M Vaysberg","year":"2007","unstructured":"Vaysberg M, Balatoni CE, Nepomuceno RR, Krams SM, Martinez OM . Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation 2007; 83: 1114\u20131121.","journal-title":"Transplantation"},{"key":"BFbmt2016269_CR35","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","volume":"105","author":"C Recher","year":"2005","unstructured":"Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105: 2527\u20132534.","journal-title":"Blood"},{"key":"BFbmt2016269_CR36","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 2015; 126: 1033\u20131040.","journal-title":"Blood"},{"key":"BFbmt2016269_CR37","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","volume":"33","author":"YL Kasamon","year":"2015","unstructured":"Kasamon YL, Bolanos-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol 2015; 33: 3152\u20133161.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016269_CR38","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","volume":"125","author":"SR McCurdy","year":"2015","unstructured":"McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolanos-Meade J, Rosner GL et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015; 125: 3024\u20133031.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2016269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016269","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:10:03Z","timestamp":1648062603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2016269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,7]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["BFbmt2016269"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.269","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,7]]},"assertion":[{"value":"8 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}